澳大利亚将为患心脏病的肥胖病人提供Wegovy基金,这需要高血压指数或特定族裔标准。 Australia will fund Wegovy for obese patients with heart disease, requiring high BMI or specific ethnic criteria.

澳洲将透过其公共卫生系统, 为肥胖症及心血管疾病患者(如心脏病发作或中风者)提供减重药物Wegovy(semaglutide)补贴。 Australia will subsidize the weight-loss drug Wegovy (semaglutide) through its public health system for people with obesity and established cardiovascular disease, such as those who’ve had a heart attack or stroke. 公共边界管制委员会建议的搬迁限制某些族裔群体进入拥有35岁或以上,或32.5岁或以上BMI的人进入BBAC。 The move, recommended by the PBAC, limits access to those with a BMI of 35 or higher, or 32.5 or higher for certain ethnic groups. 虽然该药物尚不能用于更广泛的肥胖症治疗,但专家们强调需要饮食支持,以防止副作用。 While the drug is not yet available for broader obesity treatment, experts stress the need for dietitian support to prevent side effects. 政府将与诺沃·诺迪斯克合作,最终确定这一名单,世界卫生组织敦促改善全球获得GLP-1药物的机会。 The government will work with Novo Nordisk to finalize the listing, with the World Health Organization urging improved global access to GLP-1 medications.